Andexanet Alfa

5 trials 2 recruiting VVarious

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

2 Completed trials

5 Sponsors

22 Countries

Phase III

Phase II

Phase IV

Phase III: 2 Phase II: 1 Phase IV: 2

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Atrial fibrillation 1 Ischaemic stroke 1

Sponsors using this IMP

Academisch Ziekenhuis Leiden 1 Amsterdam UMC Stichting 1 AstraZeneca AB 1 Janssen - Cilag International 1 Medical University Of Gdansk 1

All trials

5 total

Weight-loss Effects aNd absorption of Direct oral anticoagulants in roux-en-Y gastric bypass patients: a prospective study (WENDY) Pending

2024-519737-30-00 Phase IV 1 country Amsterdam UMC Stichting
DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t… Recruiting

2023-510186-98-00 Phase IV 1 country Academisch Ziekenhuis Leiden
A multicentre study evaluating the safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtP… Recruiting

2024-518509-17-00 Phase II 1 country Medical University Of Gdansk
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Phase III 19 countries Janssen - Cilag International
A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended

2022-501353-37-00 Phase III 19 countries Astrazeneca AB

Showing 1–5 of 5 trials

← All drugs A–Z